Update: This morning, Bristol-Myers Squibb announced that its immunotherapy, Opdivo, also delayed cancer progression more than Afinitor in kidney cancer. This raises questions about the sales potential of Exelixis’ drug. On September 2, 2014, shares in Exelixis, a drug maker that has spent two decades trying to turn the early fruits of genetic research into […]